$AKBA News
Last published 6d ago
- 6d agoAKBAAkebia Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02
- 6d agoAKBAAkebia Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewswirePatients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of
- 6d agoAKBAAkebia's Third Quarter 2026 Financial Results - AKEBIA THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Akiva's third quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer
- 6d agoAKBAAkebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining HemoglobinGlobeNewswireWALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 1w agoAKBAAkebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business HighlightsGlobeNewswireWALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2026, on Thursday, November
- 2w agoAKBAU.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney WeekGlobeNewswireWALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S.
- 1mo agoAKBAAkebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumGlobeNewswireWALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that
- 1mo agoAKBAAkebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesGlobeNewswireOpen-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia
- 2mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one
- 2mo agoAKBAAkebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in BostonGlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 3mo agoAKBAAkebia Therapeutics Reports Second Quarter 2026 Financial Results and Business HighlightsGlobeNewswireQ2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket
- 3mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2
- 3mo agoAKBAAkebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney DiseasesGlobeNewswireCAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the
- 3mo agoAKBAAkebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business HighlightsGlobeNewswireCAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on Wednesday, August 5,
- 4mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3
- 4mo agoAKBAU.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESAGlobeNewswireVafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent
- 5mo agoAKBAAkebia Therapeutics Strengthens Vafseo® (vadadustat) Patent PortfolioGlobeNewswireCAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 5mo agoAKBAJefferies Global Healthcare Conference in New York - AKEBIA THERAPEUTICS INCEarnings Call Transcriptsall right welcome everyone to jeffrey's 2026 global healthcare conference my name is roger song covering smith cat biotech so it is my pleasure to have the fireside chat with our company akibia therapeutics and then we h
- 5mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one
- 5mo agoAKBAAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 6mo agoAKBAAkebiau2019s First Quarter 2026 Financial ResultsAKEBIA THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to Akibia's first quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be
- 6mo agoAKBAAkebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline HighlightsGlobeNewswireQ1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025
- 6mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7
- 6mo agoAKBAAkebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of NephrologyGlobeNewswireCAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 6mo agoAKBAAkebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business HighlightsGlobeNewswireAkebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for
- 7mo agoAKBAAkebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090GlobeNewswireCAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 7mo agoAKBAAkebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation SymposiumGlobeNewswireCAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 7mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 13
- 7mo agoAKBAAkebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 7mo agoAKBAApproval of Vafseo, Nda #215192 (Labeling)FDA Approved DrugsApproval Date: 04/01/2026; Drug Name: Vafseo, Nda #215192; Active Ingredients: VADADUSTAT; Company: Akebia; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215192
- 8mo agoAKBAAkebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 8mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five
- 8mo agoAKBAAkebia's Fourth Quarter 2025 Financial ResultsAKEBIA THERAPEUTICS INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the KBS 4th Quarter 2025 Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a qu
- 8mo agoAKBAAkebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline HighlightsGlobeNewswireQ4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat)
- 8mo agoAKBAAkebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business HighlightsGlobeNewswireCAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on
- 9mo agoAKBAAkebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireCAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 9mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two
- 10mo agoAKBAAkebia Therapeutics Announces Corporate Updates and 2026 Pipeline OutlookGlobeNewswirePositioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomerulosclerosis
- 10mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one
- 11mo agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two
- 11mo agoAKBAQTTBAkebia Announces Establishment of Rare Kidney Disease PipelineGlobeNewswireAcquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2
- 11mo agoQTTBAKBAQ32 Bio Sells Complement Inhibitor ADX-097PR NewswireQ32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...
- 11mo agoAKBAAkebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 1y agoAKBAAkebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireVafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter;
- 1y agoAKBAVafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAsGlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 1y agoAKBAAkebia Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 1y agoAKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three
- 1y agoAKBAAkebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business HighlightsGlobeNewswireCAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025, on Monday,
- 1y agoAKBAAkebia Therapeutics Provides Update on Vafseo for Non-Dialysis PatientsGlobeNewswireCAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
- 1y agoAKBAAkebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025GlobeNewswireCAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced